
Final analysis reports a lack of overall survival benefit with datopotamab deruxtecan in HR+/HER2– breast cancer compared to chemotherapy
However, secondary endpoints of the TROPION-Breast01 continue to support a potential benefit of the antibody-drug conjugate in previously treated patients